新发大流行背景下人群间疫苗分配策略的比较性能
研究使用易感-暴露-感染-恢复(SEIR)模型,考察在两个人群间分配疫苗的最优决策,考虑人群特征、疫苗效力、病原体传播性和交付速度与时机等因素。在所考虑的广泛特征范围内,按人口规模比例分配疫苗在最小化累计感染数方面表现优于或不劣于非比例分配策略。作者认为这些结果可能支持在新发病原体引起的流行中于不同地点间共享疫苗。
要点
- 按人口比例分配疫苗在最小化累计感染数上优于或不劣于非比例分配策略。
- 研究使用SEIR模型评估两个人群间疫苗分配,考虑人群、疫苗、病原体和交付特征。
- 作者认为结果可能支持在新发病原体流行中于不同地点间共享疫苗。
核心结论
- 在所考虑的广泛特征范围内,按人口规模比例分配疫苗在最小化累计感染数方面表现优于或不劣于非比例分配策略。
- 作者认为这些结果可能支持在新发病原体引起的流行中于不同地点间共享疫苗。
研究设计与样本
- 使用易感-暴露-感染-恢复(SEIR)模型研究两个人群间的最优疫苗分配决策。
主要发现
- 考虑人群特征(规模、基础免疫、异质性风险结构、交互)、疫苗效力、病原体传播性和交付速度与时机等因素。
- 按人口比例分配在最小化累计感染数方面优于或不劣于非比例分配策略。
临床怎么用
- 作者认为结果可能支持在新发病原体流行中于不同地点间共享疫苗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccine allocation decisions during emerging pandemics have proven to be challenging due to competing ethical, practical, and political considerations. Complicating decision making, policy makers need to consider vaccine allocation strategies that balance needs both within and between populations. When vaccine stockpiles are limited, doses should be allocated in locations to maximize their impact. Using a susceptible-exposed-infectious-recovered (SEIR) model we examine optimal vaccine allocation decisions across two populations considering the impact of characteristics of the population (e.g., size, underlying immunity, heterogeneous risk structure, interaction), vaccine (e.g., vaccine efficacy), pathogen (e.g., transmissibility), and delivery (e.g., varying speed and timing of rollout). Across a wide range of characteristics considered, we find that vaccine allocation proportional to population size (i.e., pro-rata allocation) performs either better or comparably to nonproportional allocation strategies in minimizing the cumulative number of infections. These results may argue in favor of sharing of vaccines between locations in the context of an epidemic caused by an emerging pathogen, where many epidemiologic characteristics may not be known.
引用
- Joshi K, Rumpler E, Kennedy-Shaffer L, et al. Comparative performance of between-population vaccine allocation strategies with applications for emerging pandemics. Vaccine. 2023. PMID: 36697312. doi:10.1016/j.vaccine.2022.12.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。